| 8.24 0.24 (3%) | 10-30 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 11.04 | 1-year : | 12.81 |
| Resists | First : | 9.45 | Second : | 10.97 |
| Pivot price | 8.45  |
|||
| Supports | First : | 7 | Second : | 5.82 |
| MAs | MA(5) : | 8.37  |
MA(20) : | 8.48 |
| MA(100) : | 9.74 |
MA(250) : | 10.44 |
|
| MACD | MACD : | -0.3 |
Signal : | -0.3 |
| %K %D | K(14,3) : | 51.6 |
D(3) : | 51.2 |
| RSI | RSI(14): 48.2 |
|||
| 52-week | High : | 33.59 | Low : | 3.01 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ AKTX ] has closed above bottom band by 49.5%. Bollinger Bands are 44% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 33 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 8.81 - 8.85 | 8.85 - 8.89 |
| Low: | 8.12 - 8.16 | 8.16 - 8.21 |
| Close: | 8.37 - 8.44 | 8.44 - 8.51 |
Akari Therapeutics, Plc, an oncology company, develops antibody-drug conjugates (ADC) for cancer-killing toxins. Its lead payload is PH1 to disrupt the function of spliceosomes and to trigger an immune response that leads to additional cancer cell killing. The company’s lead product candidate is AKTX-101, a preclinical stage trop2-targeting ADC that combines PH1 with the trop2 antibody to treat solid tumor cancer types, including lung, breast, bladder, head and neck, gastric, pancreatic, colon, prostate, and others. Its payloads include PH1 is a novel payload that is a spliceosome modulator designed to disrupt RNA splicing within cancer cells. The company also develops AKTX-102, a novel bispecific ADC that utilizes PH1 as its payload to treat various solid tumor cancers. Akari Therapeutics, Plc is headquartered in Tampa, Florida.
Sat, 31 Oct 2026
Akari Therapeutics, Plc (AKTX) Stock Price, News, Quote & History - Yahoo! Finance Canada
Fri, 30 Oct 2026
Akari Therapeutics shareholders approve increase in shares for 2023 equity plan - Investing.com Nigeria
Fri, 30 Oct 2026
Akari Therapeutics to Highlight Novel RNA-Splicing ADC Payload Strategy at the 3rd Annual ADC Payload Summit - GlobeNewswire
Fri, 23 Oct 2026
Akari Therapeutics Plc Estimates – NASDAQ:AKTX - TradingView
Mon, 19 Oct 2026
Weekly Recap: AKTX-101 mid-2027 Phase 1 target and Vatnak Vat-Ho CBO - TradingView
Thu, 15 Oct 2026
Akari Therapeutics, plc Advances Aktx-101 Toward Planned Phase 1 Clinical Development - marketscreener.com
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 2 (M) |
| Shares Float | 1 (M) |
| Held by Insiders | 16.3 (%) |
| Held by Institutions | 10.5 (%) |
| Shares Short | 15 (K) |
| Shares Short P.Month | 30 (K) |
| EPS | 0 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 10.61 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -19.2 % |
| Return on Equity (ttm) | -140.1 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -11 (M) |
| Levered Free Cash Flow | -9 (M) |
| PE Ratio | 0 |
| PEG Ratio | 0 |
| Price to Book value | 0.79 |
| Price to Sales | 0 |
| Price to Cash Flow | -1.8 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|